While clinical trials for FDA approval for use of GLP-1/GIP medications in the treatment of T1D are ongoing, the consensus statement emphasizes several key principles for safe use in the meantime: Insulin safety comes first People with type 1 diabetes should never stop taking insulin while using a GLP-1 or GIP medication
As outlined earlier, these medications lower blood sugar through multiple mechanisms: they increase insulin secretion in response to high blood glucose levels, inhibit the liver from releasing excess glucose into the bloodstream, and improve overall insulin sensitivity
Use of ferulic acid in the management of diabetes mellitus and its complications

The intensive treatment of the multiple risk factors reduces the development/progression of renal disease18 which is why guidelines insist on comprehensive management of the patient with diabetes (glycemic control and control of cardiovascular risk factors, use of renin-angiotensin system inhibitors, as well as lifestyle changes, including smoking cessation or weight loss in overweight/obese individuals, among others).19 However, the residual renal risk remains very high in optimally treated patients.20 More recently, iSGLT2 has been shown to reduce the risk of cardiovascular and renal events, but still, the residual risk of renal disease progression remains high.21,22 Nevertheless, although the rate of diabetes-related complications (such as myocardial infarction, stroke, lower limb amputations or mortality) have decreased significantly in recent decades, this is not the same for CKD patients requiring renal replacement therapy attributed to diabetic kidney disease (DKD).23 Therefore new treatments are needed that improve glycemic control independently of GFR, with a low risk of hypoglycemia and able to reduce cardiovascular and renal risk in this population

In these studies, people took Vyvanse or a placebo (a treatment containing no active drug) for 12 weeks